Intended for healthcare professionals

Research News

Anticoagulant trial to prevent recurrent stroke stops early because of risk of bleeding

BMJ 2018; 361 doi: (Published 16 May 2018) Cite this as: BMJ 2018;361:k2160
  1. Jacqui Wise
  1. London

A trial comparing rivaroxaban with aspirin for the prevention of recurrent stroke had to be stopped early because of a lack of benefit and a risk of bleeding associated with the anticoagulant.

The study,1 published in the New England Journal of Medicine, found that rivaroxaban was not superior to aspirin in preventing recurrent stroke after an initial embolic stroke of undetermined source and was associated with a …

View Full Text

Log in

Log in through your institution


* For online subscription